<div id="readability-page-1"><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at  HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Solid Biosciences  in a report issued on  Wednesday, August 13th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.45) for the quarter, down from their previous forecast of ($0.43). HC Wainwright  has a &#34;Buy&#34; rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.01) EPS, FY2027 earnings at ($1.75) EPS and FY2028 earnings at ($0.78) EPS.</p><p>Other analysts have also recently issued reports about the company. Barclays reduced their price target on Solid Biosciences from $15.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, May 16th. JMP Securities  restated a &#34;market outperform&#34; rating and set a $15.00 price target on shares of Solid Biosciences in a report on Friday, June 6th. Wedbush reduced their price target on Solid Biosciences from $17.00 to $14.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday. JPMorgan Chase &amp; Co. reduced their target price on Solid Biosciences from $15.00 to $13.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday. Finally, Piper Sandler decreased their target price on Solid Biosciences from $20.00 to $17.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, May 16th. Ten equities research analysts have rated the stock with a buy rating and two have issued  a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of &#34;Buy&#34; and a consensus target price of $15.00.</p><div><p><span></span><span>Get <strong>Solid Biosciences</strong> alerts:</span></p></div><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p><b>View Our Latest Report on Solid Biosciences</b></p><h2>Solid Biosciences Trading Down 7.6%</h2><p>Shares of NASDAQ SLDB opened at $6.17 on Friday. The company has a market cap of $480.46 million, a price-to-earnings ratio of -2.20 and a beta of 2.44. The stock has a 50-day moving average price of $5.59 and a two-hundred day moving average price of $4.41. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37. </p><ul><li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li></ul><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. </p><h2>Hedge Funds Weigh In On Solid Biosciences</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of SLDB. CWM LLC boosted its stake in  Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares during the last quarter.  Legal &amp; General Group Plc raised its stake in  Solid Biosciences by 208.6% in the 2nd quarter. Legal &amp; General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after acquiring an additional 4,063 shares during the period.  Ameritas Investment Partners Inc. raised its stake in  Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after acquiring an additional 4,534 shares during the period.  Corton Capital Inc. bought a new stake in shares of  Solid Biosciences during the fourth quarter valued at about $41,000.  Finally, Ground Swell Capital LLC bought a new position in shares of  Solid Biosciences in the first quarter valued at approximately $42,000. Hedge funds and other institutional investors own  81.46% of the company's stock. </p><h2>About Solid Biosciences</h2> (Get Free Report)<p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Solid Biosciences</li><li>The Significance of Brokerage Rankings in Stock Selection</li><li>How AEP Became a Critical AI Infrastructure Play</li><li>Quiet Period Expirations Explained</li><li>How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?</li><li>What is the S&amp;P/TSX Index?</li><li>Mercury Systems Up 27%: Financials Send Investors a Clear Signal</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2><p>Before you consider Solid Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p><p>While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SLDB

<p>HC Wainwright has revised its Q3 2025 earnings per share (EPS) estimate for Solid Biosciences Inc. (NASDAQ:SLDB) from ($0.43) to ($0.45). The firm maintains a "Buy" rating with a price target of $20.00. The consensus estimate for the full-year earnings is ($2.84) per share. Other analysts have also adjusted their price targets, with Barclays lowering it from $15.00 to $10.00. Solid Biosciences shares opened at $6.17, with a market cap of $480.46 million and a 12-month high of $10.37.</p>

HC Wainwright Forecasts Lower Earnings for Solid Biosciences